ACADIA Pharmaceuticalsの空売り状況は、投資家がACADIA Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

ACADIA Pharmaceuticals (NASDAQ:ACAD) 株価情報, 空売り情報

ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals Inc

Academy Sports and Outdoors, Inc. - Common Stock

Academy Sports and Outdoors Inc

ACADIA ENERGY CORP by Acadia Energy Corporation

Acadia Energy Corp

Acadia Healthcare Company, Inc. - Common Stock

Acadia Healthcare Co Inc

Acadia Realty Trust

Acadian Asset Management Inc. Common Stock

Acadian Asset Management Inc

ACADIAN TIMBER CORP ORD by Acadian Timber Corp

Acadian Timber Corp

ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) affirms FY2025 sales outlook from $1.03 billion-$1.09 billion to $1.03 billion-$1.09 billion vs $1.06 billion estimate.

News

Guidance

ACAD

ACADIA Pharmaceuticals Affirms FY2025 Sales Guidance of $1.03B-$1.09B vs $1.06B Est

ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.06 by 83.33 percent. This is a 10 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $244.32 million which beat the analyst consensus estimate of $239.34 million by 2.08 percent. This is a 18.70 percent increase over sales of $205.83 million the same period last year.

Earnings

Earnings Beats

ACADIA Pharmaceuticals Q1 EPS $0.11 Beats $0.06 Estimate, Sales $244.32M Beat $239.34M Estimate

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and lowers the price target from $25 to $22.

Price Target

Analyst Ratings

UBS Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $22

Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $28 price target.

Reiteration

Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $28 Price Target

Morgan Stanley analyst Jeffrey Hung assumes ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Equal-Weight rating and maintains Price Target of $20.

Initiation

Morgan Stanley Assumes ACADIA Pharmaceuticals at Equal-Weight, Maintains Price Target of $20

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that the journal <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cell.com%2Fmed%2Ffulltext%2FS2666-6340%252825%252900035-2&amp;esheet=54219219&amp;newsitemid=20250305303776&amp;lan=en-US&amp;anchor=Med&amp;index=1&amp;md5=4acb3d6fd8fb55be590cd53c73c7e0cc">Med</a>published results from the open-label study, DAFFODIL&#x2122;, evaluating the safety, tolerability and exploratory efficacy of DAYBUE&#xAE; (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age and older in the 12-week LAVENDER&#x2122; study, and the 40-week LILAC-1&#x2122; and 32-month LILAC-2&#x2122; open-label extension studies. Results of all four studies supported the FDA approval of DAYBUE in adults and pediatric patients two years of age or older.\
"Rett syndrome is a debilitating condition that often causes patients to lose acquired communication and motor skills starting as early as six to 18 months old which presents significant challenges for these children and their families," said Alan Percy, M.D., Professor of Pediatrics, Neurology, Neurobiology, Genetics, and Psychology at University of Alabama, Birmingham and lead DAFFODIL author. "Outcomes from DAFFODIL further underscore trofinetide's safety and tolerability across patient age groups and provide additional data to inform treatment plans and dosing for patients closer to the onset of symptoms."

Biotech

General

Acadia Pharmaceuticals Announces DAYBUE Study Results In Med Journal; Open-Label DAFFODIL Study Shows Comparable Safety For Rett Syndrome in 2-4 Age Group; Results Support FDA Approval for Ages 2+

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study (EUCT: 2024-514514-12-00) of ACP-711, formerly SAN711, in healthy volunteers.
In the study, ACP-711 was safe and generally well tolerated across all dosing cohorts. There were no serious adverse events, and all participants completed the study. Most adverse events were mild. No safety laboratory concerns, cardiovascular concerns, or abnormal neurological findings were observed.
Given the favorable safety and tolerability profile and the prioritization of essential tremor as the lead indication, Acadia Pharmaceuticals and Saniona are seeking regulatory approval to evaluate ACP-711 in elderly healthy volunteers and to test higher repeated doses. To enable this extension, the study has been temporarily paused until regulatory approval.

Acadia Pharmaceuticals And Saniona Announce Initial Results From ACP-711 (formerly SAN711) Phase 1 Study; ACP-711 Was Safe And Generally Well Tolerated Across All Dosing Cohorts. There Were No Serious Adverse Events, And All Participants Completed The Study. Most Adverse Events Were Mild. No Safety Laboratory Concerns, Cardiovascular Concerns, Or Abnormal Neurological Findings Were Observed

ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for ACADIA Pharmaceuticals, revealing an average target of $25.0, a high estimate of $28.00, and a low estimate of $20.00. A 2.91% drop is evident in the current average compared to the previous average price target of $25.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1740690062_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of ACADIA Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Neena Bitritto-Garg</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ACADIA Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of ACADIA Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of ACADIA Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ACADIA Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACAD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ACADIA Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind ACADIA Pharmaceuticals</h2>
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
<h3>ACADIA Pharmaceuticals: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3 months period, ACADIA Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 18.28% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: ACADIA Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.08%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ACADIA Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 5.99%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.47%, the company showcases effective utilization of assets.
Debt Management: ACADIA Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying ACADIA Pharmaceuticals: Insights From 5 Analyst Reviews

Cantor Fitzgerald analyst Charles Duncan reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Overweight and maintains $28 price target.

Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $28 Price Target

WIIM

Acadia Pharmaceuticals shares are trading higher after the company a Q4 EPS beat.

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $27 price target.

HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $27 Price Target

Full Year 2025 Financial Guidance
<ul>
<li>Total Revenues (U.S. only) of $1.03 to $1.095 billion</li>
<li>NUPLAZID net product sales in the range of $650 to $690 million.</li>
<li>DAYBUE net product sales (U.S. only) in the range of $380 to $405 million</li>
<li>R&amp;D expense in the range of $310 to $330 million</li>
<li>SG&amp;A expense in the range of $535 to $565 million</li>
</ul>

ACADIA Pharmaceuticals Sees FY25 Revenue $1.03B-$1.095B Vs $1.05B Est.

Earnings Misses

ACADIA Pharmaceuticals Q4 EPS $0.86, Sales $259.60M Miss $277.65M Estimate

AAOI

ABEV

ACMR

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARKO

ASTE

ATEC

AVNS

BATRA

BATRK

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$48.6K</td>
<td>44.4K</td>
<td>7.2K</td>
</tr>
<tr>
<td>ACAD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$157.6K</td>
<td>109</td>
<td>1.9K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$28.5K</td>
<td>2.8K</td>
<td>840</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$180.00</td>
<td>$43.0K</td>
<td>1.4K</td>
<td>316</td>
</tr>
<tr>
<td>EBS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.00</td>
<td>$43.8K</td>
<td>4</td>
<td>200</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$65.00</td>
<td>$29.2K</td>
<td>1.3K</td>
<td>159</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$245.00</td>
<td>$191.7K</td>
<td>141</td>
<td>125</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$37.00</td>
<td>$69.7K</td>
<td>1.0K</td>
<td>87</td>
</tr>
<tr>
<td>EXEL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$17.00</td>
<td>$29.5K</td>
<td>98</td>
<td>50</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$800.00</td>
<td>$37.5K</td>
<td>843</td>
<td>31</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 37 day(s) on March 21, 2025. This event was a transfer of 2561 contract(s) at a $27.50 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $48.6K, with a price of $19.0 per contract. There were 44426 open contracts at this strike prior to today, and today 7236 contract(s) were bought and sold. 
• For ACAD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), we notice a call option sweep that happens to be bullish, expiring in 128 day(s) on June 20, 2025. This event was a transfer of 901 contract(s) at a $20.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $157.6K, with a price of $175.0 per contract. There were 109 open contracts at this strike prior to today, and today 1920 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 20 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $28.5K, with a price of $1425.0 per contract. There were 2849 open contracts at this strike prior to today, and today 840 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 200 contract(s) at a $180.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $215.0 per contract. There were 1473 open contracts at this strike prior to today, and today 316 contract(s) were bought and sold. 
• Regarding EBS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), we observe a call option trade with bearish sentiment. It expires in 219 day(s) on September 19, 2025. Parties traded 200 contract(s) at a $11.00 strike. The total cost received by the writing party (or parties) was $43.8K, with a price of $219.0 per contract. There were 4 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding BMRN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.2K, with a price of $195.0 per contract. There were 1333 open contracts at this strike prior to today, and today 159 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 65 contract(s) at a $245.00 strike. The total cost received by the writing party (or parties) was $191.7K, with a price of $2950.0 per contract. There were 141 open contracts at this strike prior to today, and today 125 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bullish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 81 contract(s) at a $37.00 strike. The total cost received by the writing party (or parties) was $69.7K, with a price of $861.0 per contract. There were 1026 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
• For EXEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), we notice a call option trade that happens to be neutral, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 18 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $29.5K, with a price of $1640.0 per contract. There were 98 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 5 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $7518.0 per contract. There were 843 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BMRN

EXEL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

10 Health Care Stocks With Whale Alerts In Today's Session

Deutsche Bank analyst Neena Bitritto-Garg initiates coverage on ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Hold rating and announces Price Target of $22.

Deutsche Bank Initiates Coverage On ACADIA Pharmaceuticals with Hold Rating, Announces Price Target of $22

Key 2025-2026 Milestones:
<ul>
<li>Announced today that the marketing authorization application for DAYBUE&#x2122; has been submitted to the European Medicines Agency (EMA) with expected approval in the first quarter of 2026.</li>
<li>Initiation of Managed Access Programs in Europe in the second quarter of 2025, potentially resulting in the Company's first revenues from outside the U.S.</li>
<li>Enrollment of the last patient in the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome anticipated in the fourth quarter of 2025, followed by top-line results announcement in the first half of 2026.</li>
<li>Enrollment of the last patient in the RADIANT Phase 2 study of ACP-204 in Alzheimer's disease psychosis expected in the first quarter of 2026, followed by top-line results announcement in mid-2026.</li>
<li>Initiation of a Phase 2 study of ACP-204 for a second indication in Lewy Body Dementia in the third quarter of 2025.</li>
<li>The Company will host its first ever R&amp;D Day in mid-2025.</li>
<li>Annual net sales for the full-year 2025 expected to exceed $1 billion for the first time in Company history.</li>
</ul>

Acadia Pharmaceuticals Key Milestones 2025-2026 Include DAYBUE Marketing Authorization Submitted To EMA; Managed Access In Europe Starts Q2 2025; COMPASS PWS Phase 3 and RADIANT Phase 2 Enrollment and Results Timeline; ACP-204 Lewy Body Dementia Study Begins Q3 2025; 2025 Sales Expected To Exceed $1B

-- Filing marks company's first Marketing Authorization Application in Europe
Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. If granted marketing authorization, trofinetide will be the first and only approved therapy for Rett syndrome in the European Union (EU). Trofinetide is already approved in the United States and Canada for Rett syndrome in adults and pediatric patients two years of age and older.

Acadia Pharmaceuticals Submits Marketing Authorization Application To The EMA For Trofinetide For The Treatment Of Rett Syndrome

Press Releases

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

Comments

ACADIA Pharmaceuticals

空売り

ACADIA Pharmaceuticals (NASDAQ:ACAD) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル